New treatment option: 223Ra chloride, the first approved unsealed α-emitting radiopharmaceutical

A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases. After receiving 180 µCi (1.35 µCi/kg) of (223)Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat (223)Ra chloride administrations. (223)Ra chloride is the first Food and Drug Administration-approved unsealed α-emitting radiopharmaceutical.